BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18794669)

  • 21. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
    Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
    Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open, non-randomised comparison of escitalopram and duloxetine for the treatment of subjects with Generalized Anxiety Disorder.
    PierĂ² A; Locati E
    Hum Psychopharmacol; 2011 Jan; 26(1):63-71. PubMed ID: 21305612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. False conclusions regarding duloxetine's purported efficacy in pain among depressed patients.
    Spielmans GI
    Psychiatr Danub; 2010 Dec; 22(4):550; author reply 551. PubMed ID: 21169898
    [No Abstract]   [Full Text] [Related]  

  • 24. Duloxetine hydrochloride.
    Waitekus AB; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Nov; 3(11):907-8. PubMed ID: 15558861
    [No Abstract]   [Full Text] [Related]  

  • 25. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
    Lam RW; Andersen HF; Wade AG
    Int Clin Psychopharmacol; 2008 Jul; 23(4):181-7. PubMed ID: 18545055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
    Berk M; du Plessis AD; Birkett M; Richardt D
    Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
    Schatzberg AF
    J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there a place for duloxetine?
    Drug Ther Bull; 2007 Apr; 45(4):29-32. PubMed ID: 17451072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duloxetine: a dual reuptake inhibitor.
    Dugan SE; Fuller MA
    Ann Pharmacother; 2004 Dec; 38(12):2078-85. PubMed ID: 15522980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.
    Mancini M; Perna G; Rossi A; Petralia A
    Expert Opin Pharmacother; 2010 May; 11(7):1167-81. PubMed ID: 20402555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
    Pitchot W; Scantamburlo G; Ansseau M
    Psychiatr Danub; 2010 Nov; 22 Suppl 1():S106-7. PubMed ID: 21057413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.
    Volonteri LS; Colasanti A; Cerveri G; Fiorentini A; De Gaspari IF; Mauri MC; Valli A; Papa P; Mencacci C
    J Psychopharmacol; 2010 Aug; 24(8):1193-9. PubMed ID: 19406851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [FDA approval for the antidepressive drug Cymbalta].
    Krankenpfl J; 2004; 42(5-6):154. PubMed ID: 15527218
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful treatment of refractory hypochondriasis with duloxetine.
    Politi P; Emanuele E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1145-6. PubMed ID: 17493731
    [No Abstract]   [Full Text] [Related]  

  • 35. The treatment of urinary incontinence with Duloxetine.
    Basu M; Duckett J
    J Obstet Gynaecol; 2008 Feb; 28(2):166-9. PubMed ID: 18393011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duloexetine (Cymbalta) for treatment of major depressive disorder.
    Cobb C; Crichlow R
    Am Fam Physician; 2005 Sep; 72(6):1099-101. PubMed ID: 16190509
    [No Abstract]   [Full Text] [Related]  

  • 37. Physical symptoms comorbid with depression and the new antidepressant duloxetine.
    Bailey KP
    J Psychosoc Nurs Ment Health Serv; 2003 Dec; 41(12):13-8. PubMed ID: 14682027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Open-label support for duloxetine for the treatment of panic disorder.
    Simon NM; Kaufman RE; Hoge EA; Worthington JJ; Herlands NN; Owens ME; Pollack MH
    CNS Neurosci Ther; 2009; 15(1):19-23. PubMed ID: 19228176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duloxetine treatment of Premenstrual Dysphoric Disorder: case reports.
    Ramos MG; Hara C; Rocha FL
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):579-80. PubMed ID: 17897763
    [No Abstract]   [Full Text] [Related]  

  • 40. Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder.
    Liu X; Gelwicks S; Faries DE; Able SL
    Int Clin Psychopharmacol; 2010 Nov; 25(6):315-22. PubMed ID: 20706125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.